Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Raymond James & Associates

Raymond James & Associates boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 513,566 shares of the medical research company’s stock after acquiring an additional 43,660 shares during the period. Raymond James & Associates owned about 0.13% of Thermo Fisher Scientific worth $298,490,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MBL Wealth LLC raised its position in shares of Thermo Fisher Scientific by 50.9% in the first quarter. MBL Wealth LLC now owns 954 shares of the medical research company’s stock valued at $554,000 after buying an additional 322 shares during the last quarter. Windmill Hill Asset Management Ltd raised its position in shares of Thermo Fisher Scientific by 5.7% in the first quarter. Windmill Hill Asset Management Ltd now owns 2,726 shares of the medical research company’s stock valued at $1,584,000 after buying an additional 146 shares during the last quarter. Eagle Bluffs Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 1.1% in the first quarter. Eagle Bluffs Wealth Management LLC now owns 3,650 shares of the medical research company’s stock valued at $2,123,000 after purchasing an additional 38 shares during the period. Ashton Thomas Private Wealth LLC grew its holdings in Thermo Fisher Scientific by 0.9% in the first quarter. Ashton Thomas Private Wealth LLC now owns 8,058 shares of the medical research company’s stock valued at $4,684,000 after purchasing an additional 74 shares during the period. Finally, Cohen Investment Advisors LLC grew its holdings in Thermo Fisher Scientific by 18.1% in the first quarter. Cohen Investment Advisors LLC now owns 5,314 shares of the medical research company’s stock valued at $3,089,000 after purchasing an additional 816 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of a number of recent analyst reports. Barclays boosted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday. HSBC boosted their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of TMO stock traded up $1.87 on Friday, hitting $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The firm has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80. The stock’s 50 day moving average is $573.60 and its 200-day moving average is $530.40. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.39 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.